[1]刘红梅,张　月,刘晓曼,等.血清 microRNA-337 表达水平对自拟强肾健脾通络汤方剂治疗早期糖尿病肾病获益的诊断价值研究[J].现代检验医学杂志,2021,36(03):14-18.[doi:10.3969/j.issn.1671-7414.2021.03.004]
　LIU Hong-mei,ZHANG Yue,LIU Xiao-man,et al.Study on the Diagnostic Value of Serum mcroRNA-337 Expression Level in the Benefit of Self-made Qiangshen Jianpi Tongluo Decoction in the Treatment ofEarly Diabetic Nephropathy[J].Journal of Modern Laboratory Medicine,2021,36(03):14-18.[doi:10.3969/j.issn.1671-7414.2021.03.004]
点击复制

血清 microRNA-337 表达水平对自拟强肾健脾通络汤方剂治疗早期糖尿病肾病获益的诊断价值研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第36卷
期数:
2021年03期
页码:
14-18
栏目:
论　著
出版日期:
2021-05-31

文章信息/Info

Title:
Study on the Diagnostic Value of Serum mcroRNA-337 Expression Level in the Benefit of Self-made Qiangshen Jianpi Tongluo Decoction in the Treatment ofEarly Diabetic Nephropathy
文章编号:
1671-7414（2021）03-014-05
作者:
刘红梅; 张　月; 刘晓曼; 等
（唐山市中医医院，河北唐山 063000）
Author(s):
LIU Hong-mei;  ZHANG Yue;  LIU Xiao-man;  AN Zhi-wen;  WANG Qian
(Tangshan Hospital of Traditional Chinese Medicine, Hebei Tangshan 063000, China)
关键词:
微 RNA-337; 自拟强肾健脾通络汤; 早期糖尿病肾病; 治疗获益; 诊断价值
分类号:
R587.2；R392.11
DOI:
10.3969/j.issn.1671-7414.2021.03.004
文献标志码:
A
摘要:
目的　探究血清微 RNA-337（miR-337）表达水平对自拟强肾健脾通络汤方剂治疗早期糖尿病肾病获益的诊断价值研究。方法　选择 2017 年 4 月 ~2018 年 11 月在唐山市中医医院就诊的 136 例早期糖尿病肾病患者作为研究对象，根据治疗获益分为预后良好组（n=84）和预后不良组（n=52），用实时荧光定量 PCR 法（RT-qPCR）检测血清 miR-337水平，并分析其与治疗获益的关系。结果 RT-qPCR 结果显示，预后良好组治疗后 miR-337 水平低于预后不良组，差异有统计学意义（t=8.072，P=0.000）。Logistic 回归分析结果显示，高水平的估算肾小球滤过率（eGFR）是治疗获益的独立保护因素（OR=0.856，95% CI ：0.792~0.925，P=0.000），高水平的血肌酐（Scr）（OR=1.052，95% CI：1.008~1.097，P=0.019）、尿清蛋白 / 肌酐比值（UACR）（OR=1.011，95% CI：1.003~1.019，P=0.005）和 miR-337（OR=10.134，95% CI：2.993~34.315，P=0.000）是治疗获益的独立危险因素。限制性立方样条拟合 Logistic 回归分析结果显示，miR337 与治疗获益呈线性关系（非线性检验 χ2=0.76，P=0.382）。结论　血清 miR-337 表达水平对自拟强肾健脾通络汤方剂治疗早期糖尿病肾病获益有一定诊断价值。

参考文献/References:

[1] 陈玉强 , 汪年松 . 糖尿病肾病的诊治现状 [J]. 中国临床医生杂志 , 2020,48(5):508-511. CHEN Yuqiang, WANG Niansong. Diagnostic andtherapeutic situation of diabetic nephropathy[J]. Chinese Journal of Clinicians, 2020,48(5):508-511.
[2] 刘裔凯 , 罗说明 , 邓敏 , 等 . 糖尿病肾病诊断与治疗新进展 [J]. 中国动脉硬化杂志 , 2020,28(8):688-691,706. LIU Yikai, LUO Shuoming, DENG Min, et al. Progressin diagnosis and treatment of diabetic nephropathy [J].Chinese Journal of Arteriosclerosis, 2020,28(8):688-691,706.
[3] 岳芳芳 , 倪文娟 , 冷小敏 , 等 . 人白介素 10- 荧光定量 PCR 检测方法的建立及其在糖尿病肾病中的表达研究 [J]. 现代检验医学杂志 , 2019,34(4):11-14. YUE Fangfang, NI Wenjuan, LENG Xiaomin, et al.Establishment of real-time quantitative PCR assay forhuman IL-10 and its expression in diabetic nephropathy [J]. Journal of Modern Laboratory Medicine,2019,34(4):11-14.
[4] 张求霞 , 汪隆海 , 昌国庆 , 等 . 尿 液 6 种蛋白与CysC 水平检测对糖尿病肾病的诊断价值 [J]. 现代检验医学杂志 , 2019,34(1):67-71. ZHANG Qiuxia, WANG Longhai, CHANG Guoqing,et al. Clinical value of detection of 6 proteins and cystatin C in urine for early diagnosis of diabetic kidneydisease [J]. Journal of Modern Laboratory Medicine,2019,34(1):67-71.
[5] 刘晴晴 , 杜昕 , 檀金川 . 糖尿病肾病的中西医研究进展 [J]. 天津中医药 , 2019,36(2):205-208. LIU Qingqing, DU Xin, TAN Jinchuan. Research progress about diabetic nephropathy based on western medicine and traditional Chinese medicine [J]. Tianjin Journalof Traditional Chinese Medicine, 2019,36(2):205-208.
[6] PAPADEMETRIOU V, ALATAKI S, STAVROPOULOS K, et al. Pharmacological management of diabeticnephropathy[J]. Current Vascular Pharmacology, 2020,18(2): 139-147.
[7] 黄雅兰 , 黄国东 , 蔡林坤 , 等 . 壮药复方仙草颗粒治疗早期糖尿病肾病的临床疗效及对患者内皮功能、血液流变学、免疫功能的影响 [J]．中国全科医学，2020，23（24）：3086-3093． HUANG Yalan, HUANG Guodong, CAI Linkun, etal. Clinical,endothelial,hemorheological and immuneresponses in patients with early diabetic nephropathyto the treatment with Compound Xiancao Granules(azhuang medicine) [J]. Chinese General Practice,2020,23(24):3086-3093.
[8] 岳树香 , 甄云凤 , 霍丽梅 . 木丹颗粒联合西医常规治疗早期糖尿病肾病临床疗效及对患者 Toll 样受体 4/核因子 κB、转化生长因子 β1/Smad 信号通路的影响 [J]. 河北中医 , 2020,42(5):722-726. YUE Shuxiang, ZHEN Yunfeng, HUO Limei. Clinicalefficacy of Mudan granule combined with western medicine in the treatment of early diabetic nephropathy andits effect on toll-like receptor 4/ nuclear factor kappaB and transforming growth factor β1/Smad signalingpathway[J]. Hebei Journal of Traditional Chinese Medicine, 2020,42(5):722-726.
[9] 赵嘉晶 , 黄慧 , 陆卫菊 , 等 . 益气固肾汤结合厄贝沙坦片治疗早期糖尿病肾病气阴亏虚、瘀血阻络证 55例 [J]．环球中医药，2020,13(8):1354-1357. ZHAO Jiajing, HUANG Hui, LU Weiju, et al. YiqiGushen decoction and irbesartan tablets in treating 55cases of early diabetic nephropathy with Qi-Yin deficiency and blood stasis obstruction[J]. Global Traditional Chinese Medicine, 2020,13(8):1354-1357.
[10] ZHAO S M, ZHANG T, QIU Q, et al. MiRNA-337leads to podocyte injury in mice with diabetic nephrop-athy[J]. European Review for Medical and Pharmacological Sciences , 2019,23(19):8485-8492.
[11] 中华医学会糖尿病学分会微血管并发症学组 . 糖尿病肾病防治专家共识 (2014 年版 )[J]. 中华糖尿病杂志 , 2014,6(11):792-801. The Microvascular Complications Group of Chinese Diabetes Association. Expert consensus on prevention andtreatment of diabetic nephropathy (2014 edition)[J]. Chinese Journal of Diabetes Mellitusv, 2014,6(11):792-801.
[12] 中华中医药学会 . 糖尿病肾病中医防治指南 [J]. 中国中医药现代远程教育 , 2011,9(4):151-153. China Association of Chinese Medicine. Guidelines forthe prevention and treatment of diabetic nephropathy bytraditional Chinese medicine[J]. Chinese Medicine Modern Distance Education of China, 2011,9(4):151-153.
[13] XIA Liang,WU Linlin,XIA Hailong, et al. MiR-337suppresses cutaneous T-cell lymphoma via the STAT3pathway[J]. Cell Cycle (Georgetown, Tex.), 2019,18(14): 1635-1645.
[14] 胡晔 , 袁明霞 . 糖尿病肾脏疾病的早期预测指标研究进展 [J]. 中国全科医学 ,2018,21(3):360-364, 369. HU Ye, YUAN Mingxia. Advances in research on earlypredictors of diabetic kidney disease [J]. Chinese General Practice, 2018,21(3):360-364,369.
[15] CHEN Jing,YANG Yuwei, L? Zhiyang, et al. Study onthe inhibitive effect of Catalpol on diabetic nephropathy[J]. Life Sci, 2020,257:118120.
[16] XIAO Wanan, YAO Enyang, ZHENG Wei, et al. miR337 can be a key negative regulator in melanoma[J].Cancer Biology & Therapy, 2017, 18(4/6): 392-399.
[17] ZHANG Rui， ZHENG Shangen，DU Yuwen , et al.Levels of HOXB7 and miR-337 in pancreatic ductal adenocarcinoma patients[J]. Diagn Pathol, 2014,9(1):61.
[18] 李淑秀 , 邓永莲 .2 型糖尿病肾病患者血浆可溶性内皮糖蛋白水平及意义 [J]. 中国煤炭工业医学杂志 ,2020,23(1):104-108. LI Shuxiu DENG Yonglian. Plsma soluble endoglinlevel and its significance in patients with type 2 diabetes mellitus [J]. Chinese Journal of Coal Industry Medicine, 2020,23(1):104-108.
[19] 郭俊敏，祝伊琳，章敏巧，等．糖尿病肾病患者肾脏预后的临床及病理危险因素分析 [J]．中华肾脏病杂志 , 2020,36(8):631-633. GUO Junmin, ZHU Yilin, ZHANG Minqiao, et al.Clinical and pathological risk factors for renal prognosis in diabetic nephropathy patients [J]. Chinese Journalof Nephrology, 2020,36(8):631-633.
[20] 梁雅灵 , 陈 伟 , 唐 芸 , 等 . 糖尿病肾病患者血清LncRNA EXOC7 的表达及意义 [J]．四川医学 ,2019,40(10):999-1004. LIANG Yaling, CHEN Wei, TANG Yun, et al. Expression and significance of serum LncRNA EXOC7 inpatients with diabetic nephropathy [J]. Sichuan MedicalJournal, 2019,40(10):999-1004.

备注/Memo

备注/Memo:
基金项目：河北省中医药管理局科研计划项目（2020385）。
作者简介：刘红梅（1987-），女，硕士，主治中医师，主要从事糖尿病及糖尿病肾病的治疗及科研工作，E-mail：mmm95113@163.com。
更新日期/Last Update: 1900-01-01